Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications.

Authors

Katrine M Johannesen
Yuanyuan Liu
Mahmoud Koko
Cathrine E Gjerulfsen
Lukas Sonnenberg
Julian Schubert
Christina D Fenger
Ahmed Eltokhi
Maert Rannap
Nils A Koch
Stephan Lauxmann
Johanna Krüger
Josua Kegele
Laura Canafoglia
Silvana Franceschetti
Thomas Mayer
Johannes Rebstock
Pia Zacher
Susanne Ruf
Michael Alber
Katalin Sterbova
Petra Lassuthová
Marketa Vlckova
Johannes R Lemke
Konrad Platzer
Ilona Krey
Constanze Heine
Dagmar Wieczorek
Judith Kroell-Seger
Caroline Lund
Karl Martin Klein
P Y Billie Au
Jong M Rho
Alice W Ho
Silvia Masnada
Pierangelo Veggiotti
Lucio Giordano
Patrizia Accorsi
Christina E Hoei-Hansen
Pasquale Striano
Federico Zara
Helene Verhelst
Judith S Verhoeven
Hilde M H Braakman
Bert van der Zwaag
Aster V E Harder
Eva Brilstra
Manuela Pendziwiat
Sebastian Lebon
Maria Vaccarezza
Ngoc Minh Le
Jakob Christensen
Sabine Grønborg
Stephen W Scherer
Jennifer Howe
Walid Fazeli
Katherine B Howell
Richard Leventer
Chloe Stutterd
Sonja Walsh
Marion Gerard
Bénédicte Gerard
Sara Matricardi
Claudia M Bonardi
Stefano Sartori
Andrea Berger
Dorota Hoffman-Zacharska
Massimo Mastrangelo
Francesca Darra
Arve Vøllo
M Mahdi Motazacker
Phillis Lakeman
Mathilde Nizon
Cornelia Betzler
Cecilia Altuzarra
Roseline Caume
Agathe Roubertie
Philippe Gélisse
Carla Marini
Renzo Guerrini
Frederic Bilan
Daniel Tibussek
Margarete Koch-Hogrebe
M Scott Perry
Shoji Ichikawa
Elena Dadali
Artem Sharkov
Irina Mishina
Mikhail Abramov
Ilya Kanivets
Sergey Korostelev
Sergey Kutsev
Karen E Wain
Nancy Eisenhauer
Monisa Wagner
Juliann M Savatt
Karen Müller-Schlüter
Haim Bassan
Artem Borovikov
Marie Cecile Nassogne
Anne Destrée
An Sofie Schoonjans
Marije Meuwissen
Marga Buzatu
Anna Jansen
Emmanuel Scalais
Siddharth Srivastava
Wen Hann Tan
Heather E Olson
Tobias Loddenkemper
Annapurna Poduri
Katherine L Helbig
Ingo Helbig
Mark P Fitzgerald
Ethan M Goldberg
Timo Roser
Ingo Borggraefe
Tobias Brünger
Patrick May
Dennis Lal
Damien Lederer
Guido Rubboli
Henrike O Heyne
Gaetan Lesca
Ulrike B S Hedrich
Jan Benda
Elena Gardella
Holger Lerche
Rikke S Møller

Publication/Presentation Date

9-14-2022

Abstract

We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel Nav1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups were identified: Group 1, benign familial infantile epilepsy (n = 15, normal cognition, treatable seizures); Group 2, intermediate epilepsy (n = 33, mild intellectual disability, partially pharmaco-responsive); Group 3, developmental and epileptic encephalopathy (n = 177, severe intellectual disability, majority pharmaco-resistant); Group 4, generalized epilepsy (n = 20, mild to moderate intellectual disability, frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodevelopmental disorder without epilepsy (n = 20, mild to moderate intellectual disability). Those in Groups 1-3 presented with focal or multifocal seizures (median age of onset: 4 months) and focal epileptiform discharges, whereas the onset of seizures in patients with generalized epilepsy was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human Nav1.6 channels and whole-cell patch-clamping. Two variants causing developmental and epileptic encephalopathy showed a strong gain-of-function (hyperpolarizing shift of steady-state activation, strongly increased neuronal firing rate) and one variant causing benign familial infantile epilepsy or intermediate epilepsy showed a mild gain-of-function (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (reduced current amplitudes, depolarizing shift of steady-state activation, reduced neuronal firing). Functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested gain-of-function variant had either focal (n = 97, Groups 1-3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals with a loss-of-function variant had either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developmental and epileptic encephalopathy. Computational modelling in the gain-of-function group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. Gain-of-function variant carriers responded significantly better to sodium channel blockers than to other anti-seizure medications, and the same applied for all individuals in Groups 1-3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of loss-of-function variant carriers and the extent of the electrophysiological dysfunction of the gain-of-function variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that sodium channel blockers present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.

Volume

145

Issue

9

First Page

2991

Last Page

3009

ISSN

1460-2156

Disciplines

Medicine and Health Sciences | Pediatrics

PubMedID

34431999

Department(s)

Department of Pediatrics

Document Type

Article

Share

COinS